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Inhaled Antibiotics for Hospital-
Acquired and Ventilator-
Associated Pneumonia
To the Editor—We would like to com-
ment on the hospital-acquired (HAP) 
and ventilator-associated pneumonia 
(VAP) guidelines recently published in 
Clinical Infectious Diseases [1]. These 
guidelines recommend inhaled anti-
biotics for patients with VAP due to 
gram-negative bacilli susceptible only to 
aminoglycosides or polymyxins and for 
patients not responding to intravenous 
(IV) antibiotics. It also suggests adjunc-
tive inhaled colistin for HAP or VAP due
to Acinetobacter strains susceptible only
to polymyxins. Several important con-
siderations related to inhaled antibiotics
were not addressed.
In the United States, only 3 inhaled 
antibiotics are approved by the US Food 
and Drug Administration (FDA) and 
commercially available: aztreonam, 
tobramycin solution, and tobramycin 
powder. One additional product, colistin 
dry powder for inhalation, is approved by 
the European Medicines Agency. None 
of these products are approved for the 
treatment of HAP or VAP (Table 1). The 
limited number of available antibiotics 
for inhalation, along with the increasing 
incidence of respiratory infections caused 
by multidrug-resistant (MDR) organ-
isms, has prompted the practice of using 
IV antibiotics for inhaled administration. 
We believe this practice should generally 
be discouraged.
Inhalation and IV formulations of 
the same drug are not interchangeable. 
Inhalation of antibiotics not formulated 
for this route of administration has led 
to adverse effects, including death [2–5]. 
Currently approved inhaled antibiotics 
have been designed to optimize deliv-
ery to the lung. This has been achieved 
through modification of various prop-
erties for enhanced lung deposition [6]. 
The formulation should also be paired 
with the appropriate inhaler or nebulizer 
to ensure proper particle size for lung dis-
tribution and to provide dose consistency. 
Commercially available inhaled antibiotics 
have also been formulated for improved 
tolerability. For example, IV aztreonam 
contains arginine that, when administered 
via inhalation, has been associated with 
declining lung function in patients with 
cystic fibrosis. For this reason, aztreonam 
inhalation solution was formulated with-
out arginine [7]. Preservatives contained 
in some IV antibiotics can also contribute 
to airway irritation [8].
The administration of inhaled antibi-
otics in mechanically ventilated patients 
requires specialized skill, often requiring 
adjustments to ventilator settings to opti-
mize drug delivery and ventilator per-
formance. These adjustments may also 
necessitate increased sedation that may, 
in turn, prolong mechanical ventilation 
and negatively impact patient outcomes 
[9].
Another concern is the potential for 
loss of drug into the environment with 
nebulized therapy, leading to inadvert-
ent exposure to antibiotics by healthcare 
personnel. This could lead to adverse 
effects such as bronchospasm in healthy 
individuals. Environmental distribution 
of antibiotics could also lead to altered 
microbiota among exposed individuals 
as well as environmental spread of antibi-
otic-resistance genes. The latter concern 
is significant because many nebulized 
antibiotics, such as amikacin and colistin, 
have important clinical applications for 
treating MDR infections.
Evidence supporting the use of inhaled 
antibiotics for HAP and VAP is lim-
ited, consisting mostly of retrospective 
and observational studies [10]. We rec-
ommend that off-label use of inhaled 
antibiotics be evaluated for approval by 
the healthcare facility’s pharmacy and 
therapeutics committee in collaboration 
with the respiratory care department. 
Consideration should be given to provid-
ing off-label inhaled antibiotics for use 
under an FDA investigational new drug 
application and with approval from the 
healthcare facility’s institutional review 
board. Larger studies to evaluate the 
safety and efficacy of inhaled antimicro-
bial therapy for the treatment of pneumo-
nia are needed.
Table 1. Current Commercially Available Inhaled Antibiotics
Antibiotic Indication Approving Agency Availability in the United States
Aztreonam for inhalation solution To improve respiratory symptoms in cystic fibrosis patients 
aged ≥7 years with Pseudomonas aeruginosa
FDA Available
Tobramycin inhalation solution Management of cystic fibrosis patients aged ≥6 years with 
Pseudomonas aeruginosa
FDA Available
Tobramycin inhalation powder Management of cystic fibrosis patients aged ≥6 years with 
Pseudomonas aeruginosa
FDA Available
Colistimethate dry powder for 
inhalation
Management of chronic pulmonary infections due to 
Pseudomonas aeruginosa in patients with cystic fibrosis 
aged ≥6 years 
European Medicines Agency Not available
Abbreviation: FDA, US Food and Drug Administration.
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